Physician profile
Earl K Larson
NPI 1598792509
$586.02
in general payments reported to CMS, 2019-2025
17 companies · $16.47 in 2025
The $16.47 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $65.40 · 2022: $25.29 · 2023: $51.89 · 2024: $31.90 · 2025: $16.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.98 | 2019-2024 | |
| Astellas Pharma US INC | $75.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.26 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $51.11 | 2019 | |
| Pfizer INC. | $42.80 | 2019-2020 | |
| Karl Storz Endoscopy-America | $38.86 | 2020 | |
| Neotract INC. | $31.23 | 2019 | |
| Innovation Technologies INC | $25.29 | 2022 | |
| Janssen Scientific Affairs, LLC | $19.38 | 2019 | |
| 180 Medical, INC. | $18.69 | 2019 | |
| Conmed Corporation | $18.56 | 2019 | |
| Verity Pharmaceuticals INC. | $17.82 | 2023 | Trelstar |
| Urogen Pharma, INC. | $16.47 | 2025 | |
| Boston Scientific Corporation | $12.75 | 2019 | |
| Coloplast Corp | $12.46 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $11.85 | 2019 | |
| Amgen INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.